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ABSTRACT 
Atherosclerosis is an inflammatory disease. Because high plasma 
concentrations of cholesterol, in particular those of low-density 
lipoprotein (LDL) cholesterol, are one of the principal risk factors for 
atherosclerosis, the process of atherogenesis has been considered by many 
to consist largely of the accumulation of lipids within the artery wall; 
however, it is much more than that.  The lesions of atherosclerosis occur 
principally in large and medium-sized elastic and muscular arteries and 
can lead to ischemia of the heart, brain, or extremities, resulting in 
infarction. They may be present throughout a person’s lifetime. Among 
patients with established cardiovascular disease, mortality is lower among 
those who participate in an exercise program than among those who do 
not. Furthermore, recent studies have reported positive lipid-lowering 
effects from estrogen and/or progestogen in postmenopausal women but 
there are still conflicting reports on the use of these agents in 
dyslipidaemia and in females at risk for CHD. In addition to lowering 
lipid levels, these antihyperlipidaemic The new therapeutic options 
available to clinicians treating dyslipidaemia in the last decade have 
enabled effective treatment for many atherosclerotic process. 
Keywords: Atherosclerosis, Dyslipidaemia, Antihyperlipidaemic, Cholesterol, 
Atherogenesis 
 
Introduction 
Atherosclerosis is a progressive disease with a 
multifactorial pathogenesis, which involves both 
large and mid-size arteries of different districts, 
causing stenosis of some vessels and ectasia in 
others. The clinical manifestations of the disease 
are different depending on the affected district 
(ischemic heart disease, ischemic stroke, 
peripheral artery diseases). Atherosclerosis 
represents the leading cause of death and 
disability in Europe and USA (about 52%)1 and 
it is predicted to become the main cause of 
mortality and disability worldwide.2,3 The 
simultaneous presence of atherosclerotic lesions 
in at least two major vascular territories is 
defined “multisite” artery disease.4 
Atherosclerosis is implicated in 75% of all 
cardiovascular (CV) related deaths in the United 
States.5  
Factors that inﬂuence the risk of developing 
atherosclerosis occur throughout one’s lifetime; 
the disease or its precursors begin in childhood 
with asymptomatic but identiﬁable pathology 
and  then progress slowly into adulthood.6 By 
the time young adults reach their 30s, some 
degree of atherosclerosis has developed in 80% 
to 90% of young men and women in the United 
States.7 In populations with LDL cholesterol 
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levels 70 mg/dL, virtually no atherosclerosis 
occurs.8 Obesity, hypertension, diabetes 
mellitus, physical inactivity and smoking all are 
contributors to the development of 
atherosclerotic CVD.9 
Atherosclerosis mainly affects large and 
medium-sized arteries, including the aorta, the 
carotid arteries, the coronary arteries and the 
arteries of the lower extremities. The earliest 
lesion of atherosclerosis is called the fatty 
streak, which is common even in infants and 
young children.10 In patients with 
hypercholesterolaemia, this influx of cells is 
preceded by lipid deposition.10,11 The fatty streak 
is a pure inﬂammatory lesion, consisting only of 
monocyte-derived macrophages and T 
lymphocytes.12-14 Hyperlipidemia plays an 
important role in the pathogenesis of 
atherosclerosis. Numerous studies have 
demonstrated that dyslipidemia, such as the 
increases in plasma concentrations of 
triglyceride, total cholesterol (TC), and low-
density lipoprotein cholesterol (LDL-C), and a 
decrease in plasma concentration of high-density 
lipoprotein cholesterol (HDL-C), is an important 
risk factor for various cardiovascular diseases. 
Of these plasma lipids, LDL-C plays a crucial 
role in the development of atherosclerosis; 
however, the elevation of HDL-C prevents the 
initiation of atherosclerosis by blocking the 
atherogenic effects of LDL-C.15,16 
 
Figure 1: Cardiovascular disease accounts for 
one third of deaths worldwide and half of 
deaths in the developed world. Data from 
World Health Organization (2002).17,18 
These evidences indicate that improvement of 
blood lipid profile prevents blood vessel injury 
and the pathogenic development of 
atherosclerotic plaque formation leading to 
cardiovascular dysfunction. Atherosclerosis is 
also regarded as a chronic inflammatory disease 
that results from the production of various 
cytokines, such as tumor necrosis factor-a (TNF-
a) and interleukin-1b (IL-1b), as well as soluble 
mediators ,including inducible nitric oxide 
synthase  (iNOS)-mediated NO production.17,18 
Causes  
Cardiovascular diseases have remained one of 
the leading causes of death all over the world.19 
The development of these diseases has been 
linked to several factors such as high calorie diet 
intake, lack of exercise, smoking, age, alcohol 
consumption and genetic disposition.20 These 
factors ultimately result in disorders of lipid and 
lipoprotein metabolism including lipoprotein 
overproduction and deficiency.21 
Causes of hyperlipidemia could be primary or 
secondary in nature. Primary (genetic) causes 
are single or multiple gene mutations that result 
in either overproduction or defective clearance 
of triglycerides and low density lipoprotein 
cholesterol, or underproduction and excessive 
clearance of high density lipoprotein 
cholesterol.22 
Secondary causes include, among others 
diseases such as diabetes mellitus, chronic liver 
disease, hypothyroidism and primary biliary 
cirrhosis. Hyperlipidemia has also been 
associated with enhanced oxidative stress related 
to increased lipid peroxidation.23 
 
Figure 2:  Circle graph shows progression of 
plaque volumes in the 12-month period 
expressed as percent change (n=54).23 
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Importance of biomarkers in 
atherosclerosis 
Biomarker 
A biomarker is defined as a characteristic that is 
objectively measured and evaluated as an 
indicator of normal biologic processes or 
pathogenic processes or as a physiologic 
response to a therapeutic intervention. In clinical 
medicine, biomarkers are routinely used in 
disease diagnosis, prognostication, ongoing 
clinical decision-making, and follow-up to 
assess effects of therapy. Commonly used 
biomarkers include the electrocardiogram, 
isotopic and ultrasound imaging studies applied 
in multiple areas of disease management, bone 
densitometry in the assessment of osteoporotic 
fracture risk, dynamic pulmonary function 
testing, and angiography in the management of 
coronary and peripheral arterial disease. 
Commonly used soluble biomarkers include C-
reactive protein, low- and high-density 
lipoprotein cholesterol (LDL-C, HDL-C), 
triglycerides, serum creatinine, and 
hepatocellular enzymes, as well as a host of 
other routine clinical laboratory measurements. 
Cardiovascular disease (CVD), including 
myocardial infarction (MI), heart failure, and 
stroke, represents the leading cause of mortality 
worldwide, accounting for half of the total 
number of deaths in the developed world (World 
Health Organization, 2002). Furthermore, the 
increasing prevalence of diabetes and obesity, 
combined with poor adherence to clinical 
guidelines that address both therapeutic lifestyle 
changes and pharmacologic interventions 
(National Cholesterol Education Program Adult 
Treatment Panel III, 2002).24  
Validation of new surrogate markers 
Presently, there is no agreed-upon standard with 
respect to the body of evidence that must be 
developed for a biomarker to be considered a 
surrogate marker of clinical efficacy. A 
framework for the validation of biomarkers was 
proposed by24 and subsequently adapted by in a 
discussion of the usefulness of carotid 
ultrasound to measure the clinical efficacy of 
lipid-lowering medications   in modifying the 
terminology of described clinical and statistical 
characteristics that a biomarker should have to 
be considered a surrogate marker of efficacy in 
atherosclerotic disease.27  
Atherosclerosis is a systemic arterial disorder, as 
documented in numerous post-mortem studies, 
and because a patient who has developed 
atherosclerosis in one vascular bed will also 
have it in other vascular beds, such methods can 
be used to support a clinical diagnosis of 
systemic atherosclerosis and overall 
cardiovascular risk.26,28,30 
A. Quantitative coronary angiography 
B. Carotid B-mode ultrasound 
C. Coronary intravascular ultrasound 
Quantitative coronary angiography 
Coronary angiography was first used and is still 
used in the clinical setting to confirm the 
presence or absence of symptom-limiting 
atherosclerotic arterial narrowing. Typically, 
patients at risk of coronary artery disease (CAD) 
present with symptoms of angina pectoris or a 
positive stress test and, if clinical suspicion and 
concern are high, undergo diagnostic cardiac 
catheterization. Cardiac catheterization is an 
“invasive procedure” in which a catheter is 
advanced through a large vessel, typically a 
femoral artery, over the aortic arch, and 
selectively engaged into each of the major 
coronary arteries. During the catheterization, 
angiography is performed by injection of radio-
opaque contrast material into the vessels. By use 
of X-rays, images are acquired either on film or 
on a digital detector. The images are then 
analyzed for the presence of atherosclerotic 
narrowing that might require further intervention 
and “revascularization,” either with an 
intravascular device or by arterial bypass 
grafting. 
The current standard of care for patients with 
CAD is statin therapy titrated to an LDL-C 
target of 100 mg/dl (National Cholesterol 
Education Program Adult Treatment Panel III, 
2002).25 
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Figure 3: Diagnostic coronary angiogram 
with subtotal occlusion of the left anterior 
descending coronary artery. Courtesy of 
Section of Cardiovascular Medicine, Yale 
University School of Medicine.25 
Carotid B-mode ultrasound 
With the development of medical ultrasound, it 
became possible to evaluate vessel wall structure 
in both clinical practice and research. Ultrasound 
in the clinical setting is used to detect pathologic 
conditions such as aortic aneurysms, peripheral 
vascular disease of the lower extremities, and 
carotid artery stenoses in patients with 
cerebrovascular disease (stroke or transient 
ischemic attacks) and as echocardiography to 
evaluate cardiac structure and function. By using 
high-resolution ultrasound, measurements of 
vessel wall intima-media thickness and lumen 
diameter along the axis of the ultrasound beam 
may be made. Another important advantage of 
ultrasound, compared with catheter guided 
angiography, is its noninvasive nature, 
permitting serial measures of vessel structure, 
without exposing patients to risks of vascular 
injury or ionizing radiation. In recent years, 
measurement of cIMT by B-mode ultrasound 
has come to the fore as a quantitative research 
tool in the study of atherosclerosis [29]. 
Coronary intravascular ultrasound 
Coronary IVUS represents an emerging vascular 
imaging modality that is conceptually similar to 
extravascular ultrasound of the arterial wall. 
During IVUS, a miniaturized transducer is 
attached to the tip of a catheter, permitting the 
acquisition of intravascular images of the vessel 
wall. The transducer rotates at ∼1800 rpm, while 
the catheter is mechanically withdrawn at a fixed 
rate of 0.5 mm/s, acquiring serial images of 
vessel wall thickness throughout its 360° 
circumference.  Approximately 30 images/s can 
be acquired. The data obtained are analyzed by 
trained readers who, either manually or using 
semi-automated systems, outline the intimal 
lining of the vessel lumen and the external 
elastic membrane that separates the media from 
the adventitia. The difference between the cross-
sectional areas (CSA) bordered by the external 
elastic membrane and the CSA of the vessel 
lumen represents the vessel wall or atheroma 
cross-sectional area. The primary disadvantage 
of coronary IVUS is that it is an invasive 
procedure performed at the time of a cardiac 
catheterization. As such and as with any 
invasive procedure, there is a small risk of 
complications including, but not limited to, 
cardiac rhythm disturbances, vascular injury 
(such as spasm), thrombosis, dissection, or 
infection.29 
Current treatment options available 
for atherosclerosis 
It is useful to look at the past, before looking to 
the present and the future, to remind ourselves of 
what therapies were for severe heterozygous 
familial hypercholesterolemia (FH) and 
homozygous FH before the statin era. Partial 
ileal bypass, portocaval shunt, liver 
transplantation, gene therapy, and 
plasmapheresis—all of these options had 
considerable morbidity attached to them. The 
most acceptable one, plasmapheresis, has now 
been replaced with selective lowdensity 
lipoprotein (LDL) apheresis. Portocaval shunt 
reduced LDL by up to 40% in patients with 
homozygous FH, but there was the possibility of 
hepatic encephalopathy, and over the long term, 
pulmonary hypertension. Partial ileal bypass is 
like a super bile acid sequestrant, preventing 
reabsorption of bile salts. It was the intervention 
in a large, randomized, controlled angiographic 
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study, the Program on the Surgical Control of 
the Hyperlipidemias (POSCH) trial.31  
The statin era changed everything for FH. Now 
with a simple small pill with virtually no side 
effects, a 40% to 54% LDL reduction can be 
achieved in heterozygous FH patients [33-35]. 
Statins have also been tested extensively in 
children with FH. Lovastatin, Simvastatin, 
Atorvastatin, and Rosuvastatin have all been 
studied in adolescents.36-39 Another one of the 
older therapies, which is very much still a 
current therapy for FH, is the combination of 
niacin and bile acid sequestrants. This was the 
best therapy available before the statins.32 
New approaches towards 
atherosclerosis 
Hyperlipidemia as an investigator of 
inflammation: inaugurating new approaches to 
regulation of prevention. In this inaugural issue 
of Journal of the American Heart Association, 
Ammirati and colleagues in Milan add 
importantly to this body of work by presenting 
data indicating that our understanding of the 
complex interaction between lipid biology and 
inflammation may also require careful cellular 
sub-phenotyping, at least as we look toward 
novel T-cell targets for intervention. Previous 
work from several laboratories has suggested a 
role for CD4+ T cells in atherosclerotic lesion 
formation, but it has been uncertain as to 
whether specific CD4+ T cell subset might have 
greater or lesser relevance to disease 
progression. Activated T lymphocytes are 
functionally defined by the cytokines produced 
with IFNγ secreted from the Th1 cells and IL-4 
from the Th2 cells.42 More recent reports 
describe the induction of macrophage 
proliferation by oxidized LDL. In early human 
lesions most proliferating cell nuclear antigen-
positive cells were monocytes/ macrophages or 
lymphocytes.45  
A substantial portion of CD4+ cells [which are 
generally thought to be T helper (Th) 
lymphocytes] isolated from atherosclerotic 
plaques recognize oxidized LDL as an antigen 
which induces them to proliferate and to secrete 
cytokines.41-44,47 
The major classes of T lymphocytes present in 
atherosclerotic lesions are CD4+. In response to 
the local milieu of cytokines, CD4+ cells 
differentiate into the Th1 or Th2 lineage.46 
Atherosclerois and inflammation 
Atherosclerosis is an inflammatory disease. 
Because high plasma concentrations of 
cholesterol, in particular those of low-density 
lipoprotein (LDL) cholesterol, are one of the 
principal risk factors for atherosclerosis,48 the 
process of atherogenesis has been considered by 
many to consist largely of the accumulation of 
lipids within the artery wall; however, it is much 
more than that. Despite changes in lifestyle and 
the use of new pharmacologic approaches to 
lower plasma cholesterol concentrations,49,50 
cardiovascular disease continues to be the 
principal cause of death in the United States, 
Europe, and much of Asia.51,52 
In fact, the lesions of atherosclerosis represent a 
series of highly specific cellular and molecular 
responses that can best be described, in 
aggregate, as an inflammatory disease.53-57  
The lesions of atherosclerosis occur principally 
in large and medium-sized elastic and muscular 
arteries and can lead to ischemia of the heart, 
brain, or extremities, resulting in infarction. 
They may be present throughout a person’s 
lifetime. In fact, the earliest type of lesion, the 
so-called fatty streak, which is common in 
infants and young children,58 is a pure 
inflammatory lesion, consisting only of 
monocyte-derived macrophages and T 
lymphocytes.59 In persons with 
hypercholesterolemia, the influx of these cells is 
preceded by the extracellular deposition of 
amorphous and membranous lipids.58,60 
Role of endothelial dysfunction in 
atherosclerosis 
The response-to-injury hypothesis of 
atherosclerosis suggests that even before 
development of the fatty streak, damage to the 
endothelium lining the blood vessel sets the 
stage for lesion development. Originally, 
denudation of the endothelium was thought to be 
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required61, but more recent work emphasizes the 
importance of endothelial dysfunction.62,63 In 
fact, some workers have gone so far as to 
suggest that the endothelial status may be 
regarded as ‘an integrated index of all 
atherogenic and atheroprotective factors present 
in an individual’, a sort of ‘threshold switch’ that 
only when activated translates an unfavourable 
risk factor profile into actual atherosclerotic 
disease [62]. 
The endothelium is a continuous layer of cells 
that separates blood from the vessel wall. An 
active, dynamic tissue, endothelium controls 
many important functions such as maintenance 
of blood circulation and fluidity as well as 
regulation of vascular tone, coagulation and 
inflammatory responses.64 
The arterial endothelium responds to flow and to 
shear forces in the blood via a pathway that 
leads to phosphorylation of endothelial nitric 
oxide synthase (eNOS), which in turn produces 
the potent vasodilator nitric oxide (NO), thus 
leading to vasodilatation.65,66 
This response allows arteries to accommodate 
increases in flow and control changes in shear 
stress.67 Regulation of eNOS occurs through its 
attachment to proteins such as caveolin68 and by 
means of phosphorylation reactions.69 
In addition, the endothelium limits local 
thrombosis by producing tissue plasminogen 
activator, maintaining a negatively charged 
surface, and by secreting anticoagulant heparans 
and thrombomodulin.70 Endothelial dysfunction 
is characterized first by a reduction in the 
bioavailability of vasodilators, in particular NO, 
whereas endothelium-derived vasoconstrictors 
such as endothelin 1 are increased.62,71 This 
leads to impairment of endothelium-derived 
vasodilatation, the functional hallmark of 
endothelial dysfunction. Second, endothelial 
dysfunction is characterized by a specific state 
of endothelial activation, which is characterized 
by a pro-inflammatory, proliferative and 
procoagulatory state that favours all stages of 
atherogenesis.72 
CD36 and macrophages in 
atherosclerosis 
CD36 is a multi-ligand scavenger receptor 
present on the surface of a number of cells such 
as platelets, monocytes/macrophages, 
endothelial and smooth muscle cells. 
Monocyte/macrophage CD36 has been shown to 
play a critical role in the development of 
atherosclerotic lesions by its capacity to bind 
and endocytose oxidized low density 
lipoproteins (OxLDL), and it is implicated in the 
formation of foam cells. However, the 
significance of CD36 in atherosclerosis has 
recently been called into question by different 
studies, and therefore its exact role still needs to 
be clarified. The aim of this article is to carefully 
review the importance of CD36 as an essential 
component in the pathogenesis of 
atherosclerosis. Unlike other cell types, 
macrophages express a number of scavenger 
receptors that are capable of taking up oxidized 
LDL, including scavenger receptor A, scavenger 
receptor B1 (SRB1), cluster of differentiation 
(CD) 36, CD68, and scavenger receptor for 
phosphatidylserine and oxidized lipoprotein.73 
Of the receptors present, scavenger receptor A 
and CD36 appear to be the most important from 
a quantitative point of view in terms of uptake of 
modified lipoprotein. the specific role that these 
receptors play in the development of human 
atheroma remains to be determined.74  
Uptake of oxidized LDL is mediated primarily 
by CD36, which recognizes the oxidized 
phospholipids within the particle. By contrast, 
scavenger receptor A recognizes the protein 
components of the particle. Exposure to oxidized 
LDL strongly induces expression of CD36 
mRNA and protein via activation of the 
transcription factor peroxisome proliferator 
activated receptor γ (PPARγ).75,76  
Physical activity in prevention of 
atherosclerosis 
The link between physical activity and CHD was 
first established in the early 1950s and since this 
time population studies have consistently found 
high levels of physical activity to be associated 
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with reduced risk of CHD morbidity and 
mortality.77,78 
Among patients with established cardiovascular 
disease, mortality is lower among those who 
participate in an exercise program than among 
those who do not.79  
Lemaitre et al. have shown that postmenopausal 
women in such a program had reduced the risk 
of myocardial infarction by 50% with modest 
leisure-time energy expenditures, equivalent to 
30 to 45 minutes of walking for exercise three 
times a week.80 
Table 1: Prevalence of renal artery stenosis at 
the time of cardiac catheterization.81 
study Number 
of 
patients 
(n) 
Any 
RAs 
(%) 
RAs 
>50% 
(%) 
Bilateral 
RAs (%) 
Jean et 
al. 
196 33 18 NR 
Weber-
Mzell et 
al. 
177 25 11 8 
Harding 
et al. 
1,302 30 15 36 
Rihal et 
al. 
297 34 19 4 
Vetrovec 
et al.  
116 29 23 29 
Aqel et 
al. 
90 NR 28 10 
Mean 
values 
NA 30.2 19.0 17.4 
NA: not applicable; NR: not reported; RAS: renal artery 
stenosis 
Future prospects of atherosclerosis  
Statins have reduced triglycerides, and 
gemfibrozil has been shown to increase high 
density lipoprotein (HDL) levels.  Nicotinic acid 
has been made tolerable with sustained-release 
formulations, and is still considered an excellent 
choice in elevating HDL cholesterol and is 
potentially effective in reducing    lipoprotein(a) 
[Lp(a)] levels, an emerging risk factor for 
coronary heart disease (CHD). Furthermore, 
recent studies have reported positive lipid-
lowering effects from estrogen and/or 
progestogen in postmenopausal women but there 
are still conflicting reports on the use of these 
agents in dyslipidaemia and in females at risk 
for CHD. In addition to lowering lipid levels, 
these antihyperlipidaemic. The new therapeutic 
options available to clinicians treating 
dyslipidaemia in the last decade have enabled 
effective treatment for many atherosclerotic 
processes. More recently, the newer fibric acid 
derivatives have also reduced LDL to levels 
comparable to those achieved with patients.77  
Funding:      No funding sources 
Conflict of interest: None declared 
References 
1. The world health report 2000 – Health 
systems: improving performance, 2000; 
WHO, Geneva. 
2. Russell LB, Gold MR, Siegel JE, Daniels N, 
Weinstein MC. The role of cost- 
effectiveness analysis in health and 
medicine. Panel on Cost-Effectiveness in 
Health and Medicine. 
JAMA.1996;276:1172-7. 
3. Weinstein MC, Siegel JE, Gold MR, Kamlet 
MS, Russell LB. Recommendations of   the 
Panel on Cost-effectiveness in Health and 
Medicine. JAMA. 1996;276:1253-8. 
4. Tendera M, Aboyans V, Bartelink ML, 
Baumgartner I, et al. ESC Guidelines on the 
diagnosis and treatment of peripheral artery 
diseases: Document covering atherosclerotic 
disease of extracranial carotid and vertebral, 
mesenteric, renal, upper and lower extremity 
arteries: the Task Force on the Diagnosis 
and Treatment of Peripheral Artery Diseases 
of the European Society of Cardiology 
(ESC). Eur Heart J 2001;32: 2851- 2906. 
5. American Heart Association. Heart Disease 
and Stroke Statistics:  Update. Dallas, TX: 
American Heart Association, 2005. 
6. Insull W Jr. The pathology of 
atherosclerosis: plaque development and 
plaque responses to medical treatment. Am J 
Med. 2008;122(Suppl):S3-S14. 
7. Berenson GS, Pickoff AS. Preventive 
cardiology and its potential influence on the 
early natural history of adult heart disease: 
Rai AK. et al. Pharmaceutical and Biological Evaluations 2016; vol. 3 (2): 154-164. 
161 
 
©Pharmaceutical and Biological Evaluations 
 
the Bogalusa Heart Study and the Heart 
Smart Program. Am J Med Sci. 
1995;310(suppl 1):S133-S138. 
8. O’Keefe JH Jr, Cordain L, Harris WH, Moe 
RM, Vogel R. Optimal low-density 
lipoprotein is 50 to 70 mg/dl: lower is better 
and physiologically normal. J Am Coll 
Cardiol. 2004;43:2142-2146. 
9. National Cholesterol Education Program. 
Third report of the National Cholesterol 
Education Program Expert Panel on 
Detection, 
10. Evaluation and Treatment of High Blood 
Cholesterol in Adults (Adult Treatment 
Panel III): final report. Circulation. 
2002;106:3143-421. 
11. Napoli C, D Armiento FP, Mancini FP, 
Postiglione A, Witztum JL, Palumbo G et al.  
Fatty streak formation occurs in human fetal 
aortas and is greatly enhanced by maternal 
hypercholesterolemia Intimal accumulation 
of low density lipoprotein and its oxidation 
precede monocyte recruitment into early 
atherosclerotic lesions. J Clin 
Invest.1997;100:2680–90. 
12. Simionescu N, Vasile E, Lupu F, Popescu 
G, Simionescu M. Prelesional events in 
atherogenesis. Accumulation of extracellular 
cholesterol-rich liposomes in the arterial 
intima and cardiac valves of the 
hyperlipidemic rabbit. Am J Pathol. 
1986;123:109–25. 
13. Stary HC. The sequence of cell and matrix 
changes in atherosclerotic lesions of 
coronary arteries in the first forty years of 
life. Eur Heart J. 1990;11:3–19 
14. Stary HC, Chandler AB, Glagov S, Guyton 
JR, Insull W, Jr., Rosenfeld ME et al. A 
definition of initial, fatty streak, and 
intermediate lesions of atherosclerosis. A 
report from the Committee on Vascular 
Lesions of the Council on Arteriosclerosis, 
American Heart Association. Arterioscler 
Thromb. 1994;14:840–56. 
15. Stary HC. Natural history of calcium 
deposits in atherosclerosis progression and 
regression. Z Kardiol. 2000;89:28–35. 
16. Parthasarathy S, Barnett J, Fong LG. High-
density lipoprotein inhibits the oxidative 
modification of low-density lipoprotein. 
Biochimica et Biophysica Acta. 
1990;1044:275–83. 
17. Steinberg D. Oxidative modification of LDL 
and atherogenesis. Circulation. 
1997;95:1062–71. 
18. Buttery LD, Springall DR, Chester AH, 
Evans TJ, Standfield EN, Parums DV, et al. 
Inducible nitric oxide synthase is present 
within human atherosclerotic lesions and 
promotes the formation and activity of  
peroxynitrite. Laboratory Investigation. 
1996;75:77–85. 
19. Choi JH, Jeong TS, Kim DY, Kim YM, Na 
HJ, Nam KH, et al. Hematin inhibits 
atherosclerosis by inhibition of reactive 
oxygen generation and NF-kB-dependent 
inflammatory mediators in hyperlipidemic 
mice. Journal of Cardiovascular 
Pharmacology. 2003; 42:287–95. 
20. Goff DC, Bertoni AG, Kramer H, Bonds D, 
Blumenthal RS, Tsai MY, et al. 
Dyslipidemia prevalence, treatment and 
control in the multi-ethnic study of 
atherosclerosis (MESA): gender, ethnicity, 
and coronary artery calcium. Circulation. 
2006;113(5):647-56. 
21. Mitchell BD, Kammerer CM, Blangero J, 
Mahanev MC, Rainwater DL, Dyke B, et al. 
Genetic and environmental contributions to 
cardiovascular risk factors in Mexican 
Americans. The San Antonio Family Heart 
Study. Circulation.1996;94:2159-70. 
22. Syed M, Mark C, John FD. Management of 
dyslipidemia in adults. The Am Fam Physi. 
2000;1:1-12. 
23. Schaefer EJ, Levy RI. Pathogenesis and 
management of lipoprotein disorders. New 
Engl J Med. 1985;312(20):1300-10. 
24. Visavadiya NP, Narasimhacharya AV. 
Ameliorative effect of Chlorophytum 
borivilianum root on lipid metabolism in 
hyperlipidemic rats. Clin Exp Pharmacol 
Physiol. 2007;34:244-9. 
25. Boissel JP, Collet JP, Moleur P, Haugh M. 
Surrogate endpoints: a basis for a rational 
approach. Eur J Clin Pharmacol. 
1992;43:235-44. 
26. De Backer G, Ambrosioni E, Borch-Johnsen 
K, Brotons C, Cifkova R, Dallongeville J, et 
al.  European guidelines on cardiovascular 
disease prevention in clinical practice: 
Rai AK. et al. Pharmaceutical and Biological Evaluations 2016; vol. 3 (2): 154-164. 
162 
 
©Pharmaceutical and Biological Evaluations 
 
executive summary. Third Joint Task Force 
of European and Other Societies on 
Cardiovascular Disease Prevention in 
Clinical Practice. Eur Heart J. 
2003;24:1601-10. 
27. Dormandy J, Heeck L, Vig S. Lower-
extremity arteriosclerosis as a reflection of a 
systemic process: implications for 
concomitant coronary and carotid disease. 
Semin Vasc Surg. 1999;12:118-22. 
28. Espeland MA, O'Leary DH, Terry JG, 
Morgan T, Evans G, Mudra H. Carotid 
intimal-media thickness as a surrogate for 
cardiovascular disease events in trials of 
HMG-CoA reductase inhibitors. Curr 
Control Trials Cardiovasc Med. 2005;6:3. 
29. Mitchell JR, Schwartz CJ. Relationship 
between arterial disease in different sites: a 
study of the aorta and coronary, carotid, and 
iliac arteries. Br Med J. 1962;5288:1293-
301. 
30. Simon A, Gariepy J, Chironi G, Megnien 
JL, Levenson J. Intima-media thickness: a 
new tool for diagnosis and treatment of 
cardiovascular risk. J Hypertens. 
2002;20:159-69. 
31. Wofford JL, Kahl FR, Howard GR, 
McKinney WM, Toole JF, Crouse JR. 
Relation of extent of extracranial carotid 
artery atherosclerosis as measured by B-
mode ultrasound to the extent of coronary 
atherosclerosis. Arterioscler Thromb. 
1991;11:1786-94. 
32. Buchwald H, Varco RL, Matts JP, et al. The 
POSCH Group. Effect of partial ileal bypass 
surgery on mortality and morbidity from 
coronary heart disease in patients with 
hypercholesterolemia: report of the Program 
on the Surgical Control of the 
Hyperlipidemias (POSCH). N Engl J Med. 
1990;323:946–55. 
33. Kuo PT, Kostis JB, Moreyra AE, Hayes JA. 
Familial type II hyperlipoproteinemia with 
coronary heart disease: effect of 
dietcolestipol- nicotinic acid treatment. 
Chest. 1981;79:286–91. 
34. Stein EA, Strutt K, Southworth H, Diggle 
PJ, Miller E. Comparison of rosuvastatin 
versus atorvastatin in patients with 
heterozygous familial hypercholesterolemia. 
Am J Cardiol. 2003;92:1287–93. 
35. Kastelein JJP, Akdim F, Stroes ESG, et al. 
Simvastatin with or without ezetimibe in 
familial hypercholesterolemia. N Engl J 
Med. 2008;358:1431–43. 
36. Noji Y, Higashikata T, Inazu A, et al. Long-
term treatment with pitavastatin (NK-104), a 
new HMG-CoA reductase inhibitor, of 
patients with heterozygous familial 
hypercholesterolemia. Atherosclerosis. 
2002;163:157–64. 
37. Clauss SB, Holmes KW, Hopkins P, et al. 
Efficacy and safety of lovastatin therapy in 
adolescent girls with heterozygous familial 
hypercholesterolemia. Pediatrics. 
2005;116:682–8. 
38. de Jongh S, Ose L, Szamosi T, et al. 
Efficacy and safety of statin therapy in 
children with familial hypercholesterolemia: 
a randomized double-blind, placebo-
controlled trial with simvastatin. Circulation. 
2002;106:2231. 
39. McCrindle BW, Ose L, Marais AD. Efficacy 
and safety of atorvastatin in children and 
adolescents with familial 
hypercholesterolemia or severe 
hyperlipidemia: a multicenter, randomized, 
placebo-controlled trial. J Pediatr. 
2003;143:74–80. 
40. Avis HJ, Hutten BA, Gagne C, et al. 
Efficacy and safety of rosuvastatin therapy 
for children with familial 
hypercholesterolemia. J Am Coll Cardiol. 
2010;55:1121–6. 
41. Daugherty A, Rateri DL. T lymphocytes in 
atherosclerosis: the yin-yang of Th1 and 
Th2influence on lesion formation. Circ Res. 
2002;90:1039–40. 
42. Hansson GK. Cell-mediated immunity in 
atherosclerosis. Curr Op Lipidol. 
1997;8:301–11. 
43. Hansson GK. Immune mechanisms in 
atherosclerosis. Arterioscler Thromb Vasc 
Biol. 2001;21:1876–90 
44. Hansson GK. Vaccination against 
atherosclerosis: science or fiction? 
Circulation. 2002;106:1599–601 
45. Hansson GK, Libby P, Schonbeck U, Yan 
ZQ. Innate and adaptive immunity in the 
pathogenesis of atherosclerosis. Circ Res. 
2002;91:281–91 
Rai AK. et al. Pharmaceutical and Biological Evaluations 2016; vol. 3 (2): 154-164. 
163 
 
©Pharmaceutical and Biological Evaluations 
 
46. Katsuda S, Coltrera MD, Ross R, Gown 
AM. Human atherosclerosis. IV. 
Immunocytochemical analysis of cell 
activation and proliferation in lesions of 
young adults. Am J Pathol. 1993;142:1787–
93. 
47. Mosmann TR, Sad S. The expanding 
universe of T-cell subsets: Th1, Th2 and 
more. Immunol Today. 1996;17:138–46. 
48. Paulsson G, Zhou X, Tornquist E, Hansson 
GK. Oligoclonal T cell expansions in 
atherosclerotic lesions of apolipoprotein E 
deficient mice. Arterioscler Thromb Vasc 
Biol. 2000;20:10–7.  
49. National Cholesterol Education Program. 
Second report of the Expert Panel on 
Detection, Evaluation, and Treatment of 
High Blood Cholesterol in Adults (Adult 
Treatment Panel II). Bethesda, Md.: 
National Heart, Lung, and Blood Institute, 
1993; (NIH publication no. 93-3095.) 
50. Scandinavian Simvastatin Survival Study 
Group. Randomised trial of cholesterol 
lowering in 4 444 patients with coronary 
heart disease: the Scandinavian Simvastatin 
Survival Study (4S). Lancet. 
1994;344:1383-9. 
51. Shepherd J, Cobbe SM, Ford I, et al. 
Prevention of coronary heart disease with 
pravastatin in men with 
hypercholesterolemia. N Engl J Med. 
1995;333:1301-7. 
52. Breslow JL. Cardiovascular disease burden 
increases, NIH funding decreases. Nat Med. 
1997;3:600-1. 
53. Braunwald E. Shattuck Lecture — 
cardiovascular medicine at the turn of the 
millennium: triumphs, concerns, and 
opportunities. N Engl J Med. 
1997;337:1360-9. 
54. Ross R, Glomset JA. Atherosclerosis and the 
arterial smooth muscle cell: proliferation of 
smooth muscle is a key event in the genesis 
of the lesions of atherosclerosis. Science. 
1973;180:1332-9. 
55. Idem. The pathogenesis of atherosclerosis. 
N Engl J Med. 1976;295: 369-77. 
56. Ross R. The pathogenesis of atherosclerosis 
— an update. N Engl J Med. 1986;314:488-
500. 
57. Idem. The pathogenesis of atherosclerosis: a 
perspective for the 1990s. Nature. 
1993;362:801-9. 
58. Idem. Atherosclerosis: a defense mechanism 
gone awry. Am J Pathol. 1993;143:987-
1002. 
59. Napoli C, D’Armiento FP, Mancini FP, et 
al. Fatty streak formation occurs in human 
fetal aortas and is greatly enhanced by 
maternal hypercholesterolemia: intimal 
accumulation of low density lipoprotein and 
its oxidation precede monocyte recruitment 
into early atherosclerotic lesions. J Clin 
Invest. 1997;100:2680-90. 
60. Stary HC, Chandler AB, Glagov S, et al. A 
definition of initial, fatty streak, and 
intermediate lesions of atherosclerosis: a 
report from the Committee on Vascular 
Lesions of the Council on Arteriosclerosis, 
American Heart Association. Circulation. 
1994;89:2462-78. 
61. Simionescu N, Vasile E, Lupu F, Popescu 
G, Simionescu M. Prelesional events in 
atherogenesis: accumulation of extracellular 
cholesterol-rich liposomes in the arterial 
intima and cardiac valves of the 
hyperlipidemic rabbit. Am J Pathol. 
1986;123:109-25. 
62. Ross R, Glomset JA. Atherosclerosis and the 
arterial smoothmuscle cell: proliferation of 
smooth muscle is a key event in the genesis 
of the lesions of atherosclerosis. Science. 
1996;180:1332–9.  
63. Bonetti PO, Lerman LO, Lerman A. 
Endothelial dysfunction—amarker of 
atherosclerotic risk. Arterioscler Thromb 
Vasc Biol. 2003;23:168–75. 
64. Widlansky ME, Gokce N, Keaney JF, Vita 
JA. The clinical implications of endothelial 
dysfunction. J Am Coll Cardiol. 
2003;42:1149–60. 
65. Gonzalez MA, Selwyn AP. Endothelial 
function, inflammation, and prognosis in 
cardiovascular disease. Am J Med. 
2003;115:99S–106S. 
66. Dimmeler S, Fleming I, Fisslthaler B, 
Hermann C, Busse R, Zeiher AM. 
Activation of nitric oxide synthase in 
endothelial cells by Akt-dependent 
phosphorylation. Nature. 1999;399:601–5. 
Rai AK. et al. Pharmaceutical and Biological Evaluations 2016; vol. 3 (2): 154-164. 
164 
 
©Pharmaceutical and Biological Evaluations 
 
67. Scotland RS, Morales-Ruiz M, Chen Y, Yu 
J, Rudic RD, Fulton D, et al. Functional 
reconstitution of endothelial nitric oxide 
synthase reveals the importance of serine 
1179 in endothelium-dependent vasomotion. 
Circ Res. 2002;90:904–10. 
68. Brouet A, Sonveaux P, Dessy C, Balligand 
JL, Feron O. Hsp90 ensures the transition 
from the early Ca2+-dependent to the late 
phosphorylation-dependent activation of the 
endothelial nitric-oxide synthase in vascular 
endothelial growth factor-exposed 
endothelial cells. J Biol Chem. 
2001;276:32663–9. 
69. Fontana J, FultonD, Chen Y, Fairchild TA, 
McCabe TJ, FujitaN, et al. Domain mapping 
studies reveal that theMdomain of hsp90 
serves as amolecular scaffold to regulate Akt 
dependent phosphorylation of endothelial 
nitric oxide synthase and NO release. Circ 
Res. 2002;90:866–73. 
70. Harrison DG. Cellular and molecular 
mechanisms of endothelial cell dysfunction. 
J Clin Invest. 1997;100:2153–7. 
71. Behrendt D, Ganz P. Endothelial function: 
from vascular biology to clinical 
applications. Am J Cardiol 2002;90:40L–
80L 
72. Yang ZH, Richard V, von Segesser L, Bauer 
E, Stulz P, Turina M et al. Threshold 
concentrations of endothelin-1 potentiate 
contractions to norepinephrine and serotonin 
in human arteries: a new mechanism of 
vasospasm? Circulation 1990;82:188–195 
73. Anderson TJ.Assessment and treatment of 
endothelial dysfunction in coronary artery   
diseas  and implications for therapy. J Am 
Coll Cardiol. 1999;34:631–8. 
74. Li AC, Glass CK. The macrophage foam 
cell as a target for therapeutic intervention. 
Nat Med. 2002;8:1235–42. 
75. Nicholson AC. Expression of CD36 in 
macrophages and atherosclerosis. The role 
of lipid regulation and PPARg signalling. 
Trends Cardiovasc Med. 2004;14:8–12 
76. Tontonoz P, Nagy L, Alvarez JA, Thomazy 
VA, Evans RM. PPAR gamma promotes 
monocyte/macrophage differentiation and 
uptake of oxidized LDL. Cell. 1998;93:241–
52. 
77. Nagy L, Tontonoz P, Alvarez JA, Chen HW, 
Evans RM. Oxidized LDL regulates 
macrophage gene expression through ligand 
activation of PPAR gamma. Cell. 
1998;93:229–40. 
78. Morris JN, Heady JA, Raffle PA, Roberts 
CG, Parks JW. Coronary heart-disease and 
physical activity of work. Lancet. 
1953;265:1053-7. 
79. Morris JN, Heady JA, Raffle PA, Roberts 
CG, Parks JW. Coronary heart-disease and 
physical activity of work. Lancet. 
1953;265:1111-20. 
80. Oldridge N, Gottlieb M, Guyatt G, Jones N, 
Streiner D, Feeny D. Predictors of health-
related quality of life with cardiac 
rehabilitation after acute myocardial 
infarction. J Cardiopulm Rehabil. 1998; 
18:95-103. 
81. Lemaitre RN, Heckbert SR, Psaty BM, 
Siscovick DS. Leisure-time physical activity 
and the risk of nonfatal myocardial 
infarction in postmenopausal women. Arch 
Intern Med. 1995;155:2302-8. 
 
